Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC User montaukwhaler, in the non small cell lung cancer subreddit, 01 Jun 2019